Effect of Deep Brain Stimulation on Gastrointestinal (GI) Motility (SCP-Comodig)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Parkinson's disease is characterized by extra-pyramidal symptoms as well as digestive involvement with gastrointestinal motility (GI) impairment. Deep brain stimulation has been recently developed as a successful treatment for extrapyramidal symptoms. In addition, preliminary reports suggest that this therapy might be successful to relieve GI symptoms as well. The aim of this study is therefore to assess the effect of deep brain stimulation on GI voluntary as well as involuntary motility.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
patient over 18 yo
patient with Parkinson's disease implanted for deep brain stimulation
patient responders to deep brain stimulation (UPDRS improved by at least 40%)
patient covered by the french health care system
patient not taking anti-parkinsonian medication the day before evaluation
patient below 18 yo
Severe psychiatric or cognitive disorders
compulsive eating disorders
diffuse GI motility impairment (except Parkinson's disease)